Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 8, Issue 7, pp. 895-911
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 8, 2019
- Revision received November 15, 2019
- Accepted April 13, 2020
- Published first April 20, 2020.
Article Versions
- Previous version (April 20, 2020 - 00:00).
- Previous version (May 27, 2020 - 05:36).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Julia Huetter1,
- Uwe Gritzan2,
- Ilona Gutcher1,
- Wolf-Dietrich Doecke3,
- Merlin V. Luetke-Eversloh4,
- Sven Golfier4,
- Helge G. Roider5,
- Anna-Lena Frisk1,
- John Hunter6,
- Andrew Pow7,
- Andrew Drake6,
- Zurit Levine8,
- Ofer Levy8,
- Meir Azulay8,
- Inbal Barbiro8,
- Gady Cojocaru8,
- Ilan Vaknin8,
- Bertolt Kreft1, and
- Lars Roese1,*
- 1Immuno-Oncology (Research), Pharmaceuticals Division, Bayer AG, Germany.
- 2Global Biologics, Pharmaceuticals Division, Bayer AG, Cologne, Germany.
- 3Biomarker Strategy, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
- 4Biomarker Research, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
- 5Bioinformatics, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
- 6Compugen USA Inc., South San Francisco, California.
- 7New Paradigm Biosciences, Woburn, Massachusetts.
- 8Compugen Ltd., Holon, Israel.
- ↵*Corresponding Author:
Lars Roese, Bayer AG, Muellerstr 178, Berlin 13353, Germany. Phone: 4930-4681-93096, E-mail: lars.roese{at}bayer.com
July 2020
Volume 8, Issue 7
Volume 8, Issue 7
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)
Jump to section
Advertisement